Compare · DMRA vs NVO
DMRA vs NVO
Side-by-side comparison of Damora Therapeutics Inc. (DMRA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DMRA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $184.33B, about 137.9x DMRA ($1.34B).
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for DMRA).
- NVO has more recent analyst coverage (25 ratings vs 6 for DMRA).
- Company
- Damora Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $1.34B
- $184.33B
- 1M return
- -
- +6.11%
- 1Y return
- -
- -14.12%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 8
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DMRA
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
- SEC Form 10-Q filed by Damora Therapeutics Inc.
- Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director, President and CEO Jarrett Jennifer bought $252,875 worth of Ordinary Shares (12,500 units at $20.23), increasing direct ownership by 2% to 512,500 units (SEC Form 4)
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Cheng Andrew
- SEC Form 3 filed by new insider Cheng Andrew
- SEC Form EFFECT filed by Damora Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S